Decoding akathisia: The significance of dopamine and dopaminergic pathways - a case report
DOI:
https://doi.org/10.33448/rsd-v13i10.47108Keywords:
Akathisia, Antipsychotics, Movement disorders, Dopaminergic pathways, Dopamine.Abstract
Background: Dopamine and dopaminergic pathways are crucial in antipsychotic treatment and the emergence of akathisia. Understanding these mechanisms is essential for effectively managing this condition. Objective: This study aims to highlight the management of akathisia in a patient with schizophrenia while underscoring the significance of dopaminergic mechanisms in treatment. Methods: Following the CARE (CAse REports) guidelines, this study presents a case report that serves as a practical representation of clinical scenarios, contextualizing theoretical concepts through real-world examples, enhancing the understanding of rare conditions and unique treatment responses. Case Report and Discussion: A 59-year-old female patient diagnosed with schizophrenia developed severe akathisia after starting risperidone. She exhibited intense restlessness and emotional distress, requiring adjustments to her treatment regimen, including the addition of propranolol, clonazepam, and phenytoin. This case illustrates the intricate relationship between dopamine dysregulation and akathisia, emphasizing the necessity for personalized treatment strategies tailored to the patient's needs. It highlights the importance of close monitoring and flexible management in addressing adverse effects associated with antipsychotic medications. Furthermore, fostering a supportive therapeutic relationship with the mental health team and incorporating familial support significantly contributed to the patient's overall treatment success. Conclusion: Understanding dopaminergic pathways is vital for managing akathisia and schizophrenia. This study advocates for a holistic treatment approach that integrates clinical insights with psychosocial factors to improve the patient's quality of life and treatment adherence.
Downloads
References
Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PloS One, 16(9), e0257129. https://doi.org/10.1371/journal.pone.0257129
Braverman, D. (2024). Dopamine agonists and antagonists. Encyclopedia of Toxicology (p. 923–928). Elsevier.
Campos, G., Ramírez, N., Seguic, C., Strube, L., & Abufhele, M. (2021). Antipsychotic-induced akathisia: recommendations for clinical practice. Revista Chilena De-Psiquiatria y Neurologia de La Infancia y Adolescencia, 32(1), 89–96.
Demyttenaere, K., Detraux, J., Racagni, G., & Vansteelandt, K. (2019). Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: A systematic review and meta-analysis. CNS Drugs, 33(6), 549–566. https://doi.org/10.1007/s40263-019-00625-3
Friedman, J. H. (2020). Movement disorders induced by psychiatric drugs that do not block dopamine receptors. Parkinsonism & Related Disorders, 79, 60–64. https://doi.org/10.1016/j.parkreldis.2020.08.031
Lopes, M. M., Pereira, G. C. N., Veloso, B. C., Anjos, Y. C., Silva, M. de S. V., Alves, F., Vilela, B. F. C., Ribeiro, E. G., & Rocha, V. C. da S. (2024). In-depth analysis of antipsychotic-induced akathisia: An integrative literature review. Research, Society and Development, 13(10), e12131047011. https://doi.org/10.33448/rsd-v13i10.47011
Nagaoka, K., Nagayasu, K., Shirakawa, H., & Kaneko, S. (2023). Acetaminophen improves tardive akathisia induced by dopamine D2 receptor antagonists. Journal of Pharmacological Sciences, 151(1), 9–16. https://doi.org/10.1016/j.jphs.2022.10.006
Musco, S., Ruekert, L., Myers, J., Anderson, D., Welling, M., & Cunningham, E. A. (2019). Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy. Journal of Clinical Psychopharmacology, 39(4), 336–343. https://doi.org/10.1097/JCP.0000000000001061
Neto, A. (2023). Manual de medicina baseada em evidências. Ed. Sanar. 8.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Poyurovsky, M., & Weizman, A. (2020). Treatment of antipsychotic-induced akathisia: Role of serotonin 5-HT2a receptor antagonists. Drugs, 80(9), 871–882. https://doi.org/10.1007/s40265-020-01312-0
Riley, D. S., Barber, M. S., Kienle, G. S., Aronson, J. K., von Schoen-Angerer, T., Tugwell, P., Kiene, H., Helfand, M., Altman, D. G., Sox, H., Werthmann, P. G., Moher, D., Rison, R. A., Shamseer, L., Koch, C. A., Sun, G. H., Hanaway, P., Sudak, N. L., Kaszkin-Bettag, M., … Gagnier, J. J. (2017). CARE guidelines for case reports: explanation and elaboration document. Journal of Clinical Epidemiology, 89, 218–235. https://doi.org/10.1016/j.jclinepi.2017.04.026
Sienaert, P., van Harten, P., & Rhebergen, D. (2019). The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia. Handbook of Clinical Neurology, 165, 415–428. https://doi.org/10.1016/B978-0-444-64012-3.00025-3
Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. 5. Cambridge University Press.
Stewart, M., Brown, J. B., Weston, W. W., McWhinney, I. R., McWilliam, C. L., & Freeman, T. R. (1995). Patient-centered medicine: Transforming the clinical method. Sage Publications, Inc.
Sun, Z. (2013). Tips for writing a case report for the novice author. Journal of Medical Radiation Sciences, 60(3), 108–113. https://doi.org/10.1002/jmrs.18
Thippaiah, S. M., Fargason, R. E., & Birur, B. (2021). Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM! Psychopharmacology Bulletin, 51(3), 72–78.
Toy, E. C.; Briscoe, D. & Britton, B. (2013). Casos clínicos em medicina de familia e comunidade. (3.ed.). McGrawHill.
World Health Organization. (2004). ICD-10: International statistical classification of diseases and related health problems: Tenth revision (2nd ed.). World Health Organization.
Yang, H.-J., Kim, S.-G., Seo, E. H., & Yoon, H.-J. (2022). Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report. BMC Psychiatry, 22(1), 74. https://doi.org/10.1186/s12888-022-03721-9
Yin, R. K. (2015). O estudo de caso. Bookman.
Zareifopoulos, N., Katsaraki, M., Stratos, P., Villiotou, V., Skaltsa, M., Dimitriou, A., Karveli, M., Efthimiou, P., Lagadinou, M., & Velissaris, D. (2021). Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic. European Review for Medical and Pharmacological Sciences, 25(14), 4746–4756. https://doi.org/10.26355/eurrev_202101_26386
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mauro Marques Lopes; Gustavo Coutinho Nogueira Pereira; Bruna Carvalho Veloso; Yuri Costa Anjos; Mariana de Sousa Vilela Silva; Fabiana Alves; Bárbara Faria Corrêa Vilela; Edmar Geraldo Ribeiro; Vinícius Corrêa da Silva Rocha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
